Key points are not available for this paper at this time.
The phenotypic manifestation of lead toxicity includes cognitive, learning, and memory decline which is associated with neuronal injuries and death and been a major challenge in public health especially in developing countries. Thus, we explore the prophylactic potentials of luteolin in prefrontal Pb intoxication. Thirty-six (36) male Wistar Rats were used for this research and di-vided into six (6) groups of six animals each and were treated orally as follows: Group 1-Normal saline (0.5ml daily for 14 days); Group 2- PbCl3 (50mg/kg of PbCl3 daily for 14 days); Group 3- luteolin (100mg/kg of LUT daily for 14 days); Group 4- luteolin and PbCl3 (50mg/kg PbCl3 and 100mg/kg LUT daily for 14 days); Group 5- PbCl3 then luteolin (50mg/kg of PbCl3 daily for 14 days followed by 100mg/kg of LUT daily for 14 days); Group 6- luteolin then PbCl3 (100mg/kg of LUT daily for 14days followed by 50mg/kg of PbCl3 daily for 14 days). We measured cerebral oxidative redox parameters, G6PDH, IL-6, acetylcholinesterase levels, and total protein profiles using ELISA and biochemical assay kits. We also examined cerebral morphology and the Nissl profile with HE and toluidine blue staining techniques, as well as astrocytic morphology and synaptic integrity with anti-GFAP and anti-synaptophysin antibodies. As a result of Pb perturba-tion, luteolin treatment inhibits MDA, IL-6, and AChE expression while increasing antioxidant enzyme activities (SOD, GPx) and G6PDH. Furthermore, luteolin has significant prophylactic po-tential against Pb-induced neuronal injuries and modulates astrocyte actions, preserving synap-tic integrity and thus improving cognition, learning, and memory. Taken together, our findings indicate that luteolin may be a promising candidate for managing and treating Pb neural intoxi-cation.
Arietarhire et al. (Fri,) studied this question.